Terms: = Liver cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Staging
42 results:
1. MYL9 expressed in cancer-associated fibroblasts regulate the immune microenvironment of colorectal cancer and promotes tumor progression in an autocrine manner.
Deng S; Cheng D; Wang J; Gu J; Xue Y; Jiang Z; Qin L; Mao F; Cao Y; Cai K
J Exp Clin Cancer Res; 2023 Nov; 42(1):294. PubMed ID: 37926835
[TBL] [Abstract] [Full Text] [Related]
2. Clinical manifestation, staging and prognosis of hepatocellular carcinoma in Gambian patients.
Bittaye SO; Kambi A; Tekanyi MAI; Tamba S; Sanneh L; Sisawo MM; Jatta A; Fatty G; Jeng A; Jallow MS; Leigh O; Njie R
BMC Gastroenterol; 2023 Sep; 23(1):321. PubMed ID: 37730538
[TBL] [Abstract] [Full Text] [Related]
3. Effects of MFG-E8 expression on the biological characteristics of ovarian cancer cells via the akt/mTOR/S6K signalling pathway.
Li N; Wang Y; Liu L; Wang P; Wu X
J Obstet Gynaecol; 2023 Dec; 43(1):2151354. PubMed ID: 36484512
[TBL] [Abstract] [Full Text] [Related]
4. External validation of the eighth edition of the TNM classification for lung cancer in small cell lung cancer.
Tan F; Bi N; Zhang H; Li R; Wang Z; Duan J; Jiang F; Feng D; Zhang R; Bai J; Cao J; Mao N; Liang K; Yin S; Shen Y; Feng F; Zhao J; Gao Y; Mao Y; Xue Q; Gao S; He J
Lung Cancer; 2022 Aug; 170():98-104. PubMed ID: 35749952
[TBL] [Abstract] [Full Text] [Related]
5. Midkine Promotes Metastasis and Therapeutic Resistance via mTOR/RPS6 in Uveal Melanoma.
Karg MM; John L; Refaian N; Buettner C; Rottmar T; Sommer J; Bock B; Resheq YJ; Ksander BR; Heindl LM; Mackensen A; Bosch JJ
Mol Cancer Res; 2022 Aug; 20(8):1320-1336. PubMed ID: 35503453
[TBL] [Abstract] [Full Text] [Related]
6. Ligand-activated PPARδ expression promotes hepatocellular carcinoma progression by regulating the PI3K-akt signaling pathway.
Han W; Wang N; Kong R; Bao W; Lu J
J Transl Med; 2022 Feb; 20(1):86. PubMed ID: 35151320
[TBL] [Abstract] [Full Text] [Related]
7. circNFATC3 sponges miR-548I acts as a ceRNA to protect NFATC3 itself and suppressed hepatocellular carcinoma progression.
Jia C; Yao Z; Lin Z; Zhao L; Cai X; Chen S; Deng M; Zhang Q
J Cell Physiol; 2021 Feb; 236(2):1252-1269. PubMed ID: 32667692
[TBL] [Abstract] [Full Text] [Related]
8. LncRNA MT1JP inhibits the malignant progression of hepatocellular carcinoma through regulating akt.
Wu JH; Xu K; Liu JH; Du LL; Li XS; Su YM; Liu JC
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6647-6656. PubMed ID: 32633354
[TBL] [Abstract] [Full Text] [Related]
9. liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
Gabr A; Kulik L; Mouli S; Riaz A; Ali R; Desai K; Mora RA; Ganger D; Maddur H; Flamm S; Boike J; Moore C; Thornburg B; Alasadi A; Baker T; Borja-Cacho D; Katariya N; Ladner DP; Caicedo JC; Lewandowski RJ; Salem R
Hepatology; 2021 Mar; 73(3):998-1010. PubMed ID: 32416631
[TBL] [Abstract] [Full Text] [Related]
10. Enhanced mLST8 Expression Correlates with Tumor Progression in Hepatocellular Carcinoma.
Yu XN; Zhang GC; Sun JL; Zhu HR; Shi X; Song GQ; Weng SQ; Dong L; Liu TT; Shen XZ; Guo HY; Zhu JM
Ann Surg Oncol; 2020 May; 27(5):1546-1557. PubMed ID: 32157528
[TBL] [Abstract] [Full Text] [Related]
11. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to
Puhr-Westerheide D; Cyran CC; Sargsyan-Bergmann J; Todica A; Gildehaus FJ; Kunz WG; Stahl R; Spitzweg C; Ricke J; Kazmierczak PM
Cancer Imaging; 2019 Nov; 19(1):73. PubMed ID: 31727170
[TBL] [Abstract] [Full Text] [Related]
12. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract] [Full Text] [Related]
13. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth.
Yao M; Sai W; Zheng W; Wang L; Dong Z; Yao D
Curr Med Chem; 2020; 27(20):3290-3301. PubMed ID: 31232234
[TBL] [Abstract] [Full Text] [Related]
14. Overexpression of CMTM7 inhibits cell growth and migration in liver cancer.
Huang ZM; Li PL; Yang P; Hou XD; Yang YL; Xu X; Xu F
Kaohsiung J Med Sci; 2019 Jun; 35(6):332-340. PubMed ID: 30903681
[TBL] [Abstract] [Full Text] [Related]
15. LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting akt/mTOR Signaling Pathway.
Zheng YL; Li L; Jia YX; Zhang BZ; Li JC; Zhu YH; Li MQ; He JZ; Zeng TT; Ban XJ; Yuan YF; Li Y; Guan XY
Theranostics; 2019; 9(3):796-810. PubMed ID: 30809309
[No Abstract] [Full Text] [Related]
16. MicroRNA‑601 serves as a potential tumor suppressor in hepatocellular carcinoma by directly targeting PIK3R3.
Song Y; He S; Zhuang J; Wang G; Ni J; Zhang S; Ye Y; Xia W
Mol Med Rep; 2019 Mar; 19(3):2431-2439. PubMed ID: 30664174
[TBL] [Abstract] [Full Text] [Related]
17. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/akt pathway.
Xie Y; Du J; Liu Z; Zhang D; Yao X; Yang Y
J Exp Clin Cancer Res; 2019 Jan; 38(1):7. PubMed ID: 30621734
[TBL] [Abstract] [Full Text] [Related]
18. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract] [Full Text] [Related]
19. [The survival prediction model of advanced gallbladder cancer based on Bayesian network: a multi-institutional study].
Tang ZH; Geng ZM; Chen C; Si SB; Cai ZQ; Song TQ; Gong P; Jiang L; Qiu YH; He Y; Zhai WL; Li SP; Zhang YC; Yang Y
Zhonghua Wai Ke Za Zhi; 2018 May; 56(5):342-349. PubMed ID: 29779309
[No Abstract] [Full Text] [Related]
20. Role of the overexpression of TRAF4 in predicting the prognosis of intrahepatic cholangiocarcinoma.
Kang Q; Zou H; Zhou L; Liu LX; Cai JB; Xie N; Li WH; Zhang C; Shi WH; Wang LM; Zhang WH; Zhu H; Wang SF; Zhang XW
Int J Oncol; 2018 Jul; 53(1):286-296. PubMed ID: 29749456
[TBL] [Abstract] [Full Text] [Related]
[Next]
